A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Novel Treatment for Periodontal Disease Under Investigation


Supported by a $1.3 million grant from the National Institute of Dental and Craniofacial Research, Stony Brook University School of Dental Medicine and Traverse Biosciences are partnering to evaluate the preclinical safety and effectiveness of the drug TRB-N0224 in treating periodontal disease.

In 2015, Traverse Biosciences signed a licensing agreement with the Research Foundation for the State University of New York (to which Stony Brook belongs) to develop a drug to treat canine periodontal disease. The partnership has led to the development of drug candidates based on curcumins — the active ingredient in the spice turmeric — that are chemically modified to treat inflammation. The leading candidate, TRB-N0224, will be evaluated for treating periodontal disease in both companion animals and humans. At the culmination of the investigation, it is hoped the U.S. Food and Drug Administration will approve TRB-N0224 as a treatment for chronic inflammatory diseases, including periodontitis.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy